- January issue of Neurosurgical Focus devoted to MRgFUS brain research
TIRAT CARMEL, Israel, Jan. 3, 2012 /CNW/ - InSightec Ltd, the global
leader in MR guided Focused Ultrasound (MRgFUS) therapy, announced
today that it has completed enrollment in the world's first feasibility study evaluating the use of MRgFUS for treatment of Essential Tremor, using ExAblate® Neuro at University of Virginia , Charlottesville, Virginia.
Fifteen patients underwent a non-invasive ExAblate treatment to evaluate
safety and initial effectiveness of this investigational device. Most
patients, who suffered for at least 10 years, experienced tremor
improvement and no severe adverse events. They are being followed up
for three months. Patient videos can be viewed here: http://bit.ly/sRpXno , http://bit.ly/tWaOl3
ExAblate Neuro, pioneered by InSightec, combines high intensity focused
ultrasound for deep accurate lesioning of the brain, with continuous
realtime MR guidance for visualizing brain anatomy, planning and
monitoring treatment and outcome. The lesioning is performed through an
intact skull with no incisions or ionizing radiation.
Additional research using MRgFUS for chronic neuropathic pain,targeted drug delivery, and sonothrombolysis for acute ischemic stroke is described in the January issue of Neurosurgical Focus devoted to MR guided focused ultrasound applications for central
nervous system disorders.
"The safety profile of ExAblate Neuro and initial clinical efficacy are
extremely encouraging" said Dr. Jeff Elias, principal investigator,
Director of Stereotactic and Functional Neurosurgery and Associate
Professor of Neurological Surgery and Neurology, UVA. Dr. Elias
presented interim results at the European MRgFUS symposium in Rome (http://bit.ly/sVntp3) and at the Congress of Neurological Surgery in Wash DC.
Essential tremor, a very common movement disorder, affects millions of
people worldwide. They have difficulty performing everyday tasks like
drinking, eating, dressing, and writing. One third do not respond to
medication, and may consider surgery. These have well recognized risks:
high doses of ionizing radiation, complications and side effects from
MRgFUS was investigated as an alternative for these medically refractory
"ExAblate Neuro, the only MRgFUS brain system in clinical use, has
demonstrated the ability to ablate targets deep in the brain with high
precision. Encouraging initial results provide hope that this treatment
could become a significant addition for treating neurological
disorders", said Eyal Zadicario, VP of R&D and Director of InSightec's
Neuro program. "InSightec is expanding its Neuro research, to include
brain tumors, stroke and targeted drug delivery."
InSightec Ltd. is privately held by Elbit Imaging, General Electric, and
MediTech Advisors. Founded in 1999 over $150 million have been invested
in clinical and technical R&D to develop ExAblate using MR guided
Focused Ultrasound into a clinically viable technology. ExAblate has
won several awards for innovation and its potential to help mankind
including the Wall St. Journal Technology Innovation Awards and the
European Union's IST grand prize.
TIME magazine recently named Focused Ultrasound as "one of 50 best
Dr. Yoav Medan, InSightec's Chief Systems Architect, presented MRgFUS at TEDMED 2011. (http://bit.ly/sII9CT)
SOURCE InSightec Ltd
For further information: